Cocrystal Pharma (COCP) Announces Earnings Results

Cocrystal Pharma (OTCMKTS:COCP) announced its quarterly earnings results on Thursday. The company reported ($0.05) earnings per share (EPS) for the quarter, Bloomberg Earnings reports.

OTCMKTS COCP traded down $0.28 during mid-day trading on Friday, hitting $3.75. The stock had a trading volume of 11,749 shares, compared to its average volume of 60,863. Cocrystal Pharma has a twelve month low of $1.61 and a twelve month high of $9.00.

About Cocrystal Pharma

Cocrystal Pharma, Inc, formerly Biozone Pharmaceuticals, Inc, is engaged in developing medicines for use in the treatment of human viral diseases. The Company develops technologies and approaches to create antiviral drug candidates. The Company is developing antiviral therapeutics that inhibit the replication function of a virus, including the ribonucleic acid (RNA)-dependent RNA polymerase enzyme, the helicase enzyme and the NS5A protein of hepatitis C virus (HCV), and the polymerase enzymes of influenza virus and norovirus.

Read More: Outstanding Shares and The Effect on Share Price

Receive News & Ratings for Cocrystal Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cocrystal Pharma and related companies with's FREE daily email newsletter.

Leave a Reply